Data from the TRAPID-AMI clinical study have confirmed the troponin T high-sensitivity test from Roche as an approach which can offer a more rapid diagnosis of heart attack in patients with acute chest pain.
The research, published online by the Annals of Emergency Medicine, investigated the novel strategy of using a cardiac troponin T high-sensitivity test for the diagnosis of heart attack. This test could potentially reduce the observation test needed to confirm or deny heart attack from 3-6 hours to just 1 hour.
“Thanks to this new approach, we can now shorten the time to heart attack diagnosis for millions of patients presenting in emergency rooms with acute chest pain all over the world,” says Christian Mueller, professor of cardiology at the University of Basel, Switzerland, one of the study’s principal investigators. “Patients no longer have to wait for three or more hours in the emergency department, not knowing whether they have an acute, life-threatening disease or if their chest pain is caused by other reasons.”
The European Society of Cardiology adopted this accelerated diagnostic concept at their annual meeting in London, UK, in August, 2015. Their current clinical practice guidelines now support the one-hour diagnostic algorithm with high-sensitive troponin testing validated in the TRAPID-AMI study.
“Results of the TRAPID-AMI study once again demonstrate how diagnostics can influence clinical practice to contribute to better patient outcomes,” says Roland Diggelmann, chief operating officer of Roche Diagnostics.